Here are the IPOs expected across the coming week:
Alopexx (NASDAQ: ALPX)
This company is joining the NASDAQ with a listing of 3 million shares. Based on the assumed IPO price of $5.00 per share, the company estimates that it will receive net proceeds from the offering of approximately $12.3m.
It's also worth noting that, upon completion of the offering, Alopexx President and CEO Daniel Vlock will hold a majority of the voting power of the company's capital stock through his ownership of 52% of outstanding common stock.
What Does Alopexx Do?
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).
That target has been found on an expanding number of pathogens, and the company's management believes that the broad-spectrum potential of its therapeutics will allow them to be used for the prevention, treatment and mitigation of a wide range of infections.
Examples of the progress achieved by Alopexx's therapeutics can be seen with the business' vaccine candidate, AV0328. The treatment's first-in-man trial showed it to be well tolerated with no serious adverse events observed, while it also induced protective antibodies against all PNAG-expressing pathogens tested.
The company believes this vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis, and sexually transmitted diseases.
Who is Leading the ALPX IPO?
The company's public listing is being headed by ThinkEquity.
Use of ALPX IPO Proceeds
The company has indicated it will use the IPO proceeds for:
Around $5.5m to initiate a proof-of-concept trial of vaccine AV0328, including manufacturing, and correlative laboratory studies.
Approximately $4.5m to initiate a proof-of-concept trial of monoclonal antibody therapeutic in ICU patients.
The remainder for general corporate purposes, including working capital, operating expenses and capital expenditures.
Beamr Imaging (NASDAQ: BMR)
Beamr Imaging is joining the public market with a placing of 3 million shares. The company has said it expects these shares to have an initial public offering price of $5.00 each, leaving the business anticipating gross proceeds of around $15m.
What Does Beamr Imaging Do?
Beamr is a video technology and image science software company. The business says its solutions and technologies are backed by 51 International granted patents, with these allowing the business expertise in video encoding, transcoding and optimization software solutions for live and video-on-demand services.
Founded in 2009 by a team of image science experts, Beamr is backed by Verizon, Innovation Endeavors, and Disruptive. Meanwhile, the company's enterprise customers include big names like Netflix (NASDAQ: NFLX), Snapfish, ViacomCBS, Wowza and Microsoft (NASDAQ: MSFT).
Additionally, it is worth noting that the business is currently collaborating with Nvidia (NASDAQ: NVDA) to develop the world's first GPU accelerated encoding solution. Beamr says this would allow fast and easy end-user deployment combined with superior video compression rates.
Want to find out if Nvidia is the right investment for you? CLICK HERE to read our analysis!
Who is Leading the BMR IPO?
Beamr Imaging's listing is being headed by ThinkEquity.
Use of BMR IPO Proceeds
Beamr says it currently expects to use the net proceeds from this offering for the following purposes:
Roughly $4.7m for research and development efforts.
$2.7m for sales and marketing activities.
Around $2.7m for cloud operating costs.
Approximately $3m for general and administrative corporate purposes, including working capital and capital expenditures.
Castellum (NYSEAMERICAN: CTM)
This offering consists of a total of 3.2 million shares of common stock, though 520,000 of these shares are being contributed by selling stockholders. The company will not receive any of the proceeds from the sale of stock by its existing stockholders.
Castellum has said it expects the public offering price to be between $3 and $5 per share.
While it is joining the NYSEAMERICAN under the CTM ticker, the business' common stock is currently quoted on the OTC Pink Marketplace under the trading symbol ONOV.
What Does Castellum Do?
Castellum is focused on acquiring and growing technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare and information operations with businesses in the governmental and commercial markets.
The company's offerings include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, and data analytics.
These services are applicable to customers in the federal government, financial services, healthcare and other users of large data applications. For example, the business' primary customers are currently agencies and departments of the US Federal, state and local governments.
The company has completed six acquisitions over the previous three years and has a pipeline of identified acquisition targets. Additionally, the business claims to have a qualified business opportunity pipeline of over $400m.
Who is Leading the CTM IPO?
This listing is being helmed by EF Hutton, a division of Benchmark Investments, LLC.
Use of CTM IPO Proceeds
The business currently expects to use approximately $2.75m of the proceeds for repayment of debt, while $3m is earmarked to fund additional acquisitions and approximately $1m for working capital and general corporate purposes.
However, Castellum also pointed out that it currently has no agreements or commitments for any acquisitions and no guarantee can be made that it will make such acquisitions in the future.
The repayment of debt of approximately $2,750,000 is to satisfy, in part, principal and interest remaining under the amended and restated convertible promissory note payable to the Buckhout Charitable Remainder Trust in the principal amount of $3.7m.
Want to learn about this week's key earnings updates? Read our Earnings Preview to get the inside track!
